Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Mar 2, 2026 · Filed Mar 3, 2026
Moderna's Chief Legal Officer sold $726K of Moderna shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$726,047
Shares × reported transaction price
17 days after results of Feb 13, 2026, 60 days before results of May 1, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $52.845 on Mar 2, 2026, within 2% of its 52-week high, after a 34% rise over the previous 30 trading days
52-week range $22.36 (Nov 20, 2025) to $53.57 (Feb 27, 2026), 98% of the way up, from 251 adjusted closes. 30 trading days earlier: $39.36 on Jan 15, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Aug 9, 2024 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.
Wentz v. Moderna, Inc., docket 1:24-cv-12058, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -3.2% | -1.3% | -1.9% |
| 30 days | -15.6% | -3.8% | -11.8% |
| 90 days | -21.0% | +10.9% | -31.9% |
| 180 days | +142.8% | +12.0% | +130.8% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
Derivative exercise or conversion — not an open-market buy.
